Palbociclib & HER2+ Breast Cancer: Longer PFS
A significant advancement in the treatment of a particularly aggressive form of breast cancer has been published today in the New England Journal of Medicine. The PATINA study demonstrates that adding palbociclib to standard treatment extends progression-free survival by nearly 15 months in patients with hormone receptor-positive (HR+), HER2-positive metastatic breast cancer – a subtype … Read more